StockCIK 886163
LIGAND PHARMACEUTICALS INC (LGND): Insider Trades and Fund Holdings
In the past 12 months, LIGAND PHARMACEUTICALS INC insiders reported 0 open-market purchases worth $0 and 5 sales worth $14.6M; 3 of the sales were reported as made under a 10b5-1 trading plan.
0Insider buys, 12 months
$0Bought by insiders, 12 months
$14.6MSold by insiders, 12 months
0Tracked funds holding
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 6, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Oct 6 | Andrew ReardonGeneral Counsel | ▼ SELL10b5-1 | $1.52M |
| Sep 14 | Martine ZimmermannDirector | ▼ SELL | $342K |
| Sep 8 | Andrew ReardonGeneral Counsel | ▼ SELL10b5-1 | $1.43M |
| Aug 14 | Octavio EspinozaCFO | ▼ SELL10b5-1 | $9.24M |
| Aug 14 | Jason HaasDirector | ▼ SELL | $2.09M |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Andrew Reardon | General Counsel | 0 | $0 | 2 | $2.95M |
| Martine Zimmermann | Director | 0 | $0 | 1 | $342K |
| Octavio Espinoza | CFO | 0 | $0 | 1 | $9.24M |
| Jason Haas | Director | 0 | $0 | 1 | $2.09M |
ADVERTISEMENT
320 × 100 ad slot
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →